Skip to main content
Equibles

Michael Severino

Chairman

AbbVie Inc. (ABBV)

Equibles does not estimate personal net worth.

Get an email with a short summary when AbbVie Inc. publishes a filing, an earnings call transcript or a press release.

Get ABBV alerts

About Michael Severino

Michael Severino is recorded as Chairman at AbbVie Inc. (ABBV). The proxy statement of AbbVie Inc. reports total compensation of $9,508,448 for Michael Severino in fiscal 2019, including a base salary of $1,330,000. Disclosed compensation is on record for 3 fiscal years. Michael Severino has spoken on 5 earnings calls across 1 company, most recently for AbbVie Inc. on October 29, 2021. AbbVie Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at AbbVie Inc. includes Robert A. Michael (CEO, Chairman, CFO, COO and Board Member), Richard A. Gonzalez (Chairman), Scott T. Reents (CFO) and 5 others.

Michael Severino on recent calls

“I'll start with immunology, where we had several regulatory updates and data readouts for both Rinvoq and Skyrizi across therapeutic areas.”
Chairman, AbbVie Inc. Q3 FY2021 Earnings Call ·
“I'll start with immunology where we had several notable pipeline events in the quarter. In the area of inflammatory bowel disease, we reported positive top line results from the Phase 3 maintenance studies for RINVOQ in ulcerative colitis, and SKYRIZI in Crohn's disease.”
Chairman, AbbVie Inc. Q2 FY2021 Earnings Call ·
“We've clearly made significant progress with our pipeline over the past few years, particularly our late-stage programs in hematologic oncology with IMBRUVICA and VENCLEXTA, and in immunology with RINVOQ and SKYRIZI.”
Chairman, AbbVie Inc. Q4 FY2020 Earnings Call ·
“We continue to make great progress across all stages of our pipeline and this morning I will highlight key events since our last earnings call.”
Chairman, AbbVie Inc. Q3 FY2020 Earnings Call ·
“We had a very productive quarter with continued progress across all stages of our pipeline. Additionally, with the recent closing of the Allergan acquisition, we added promising pipeline assets in the areas of aesthetics and neuroscience.”
Chairman, AbbVie Inc. Q2 FY2020 Earnings Call ·

Affiliation history

Company network

Leadership on record at AbbVie Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2019 AbbVie Inc. (ABBV) $1,330,000 $9,508,448
2018 AbbVie Inc. (ABBV) $1,100,605 $8,607,359
2017 AbbVie Inc. (ABBV) $1,004,460 $8,395,276

Recent activity